J. Goldman & CO LP Ventyx Biosciences, Inc. Transaction History
J. Goldman & CO LP
- $3.53 Billion
- Q4 2024
Shares
1 transactions
Others Institutions Holding VTYX
# of Institutions
134Shares Held
55.2MCall Options Held
81.4KPut Options Held
148K-
Black Rock Inc. New York, NY4.77MShares$8.21 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.48MShares$7.71 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC4.27MShares$7.35 Million0.0% of portfolio
-
Sio Capital Management, LLC New York, NY4.05MShares$6.96 Million3.31% of portfolio
-
Ubs Group Ag3.78MShares$6.51 Million0.0% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $97.2M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...